SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Mutation Q28D

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There are 2 clinical trials

Clinical Trials


1 A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 403 in Younger and Older Subjects With Osteoarthritis Knee Pain

This is a sequential, randomized, double-blind, placebo controlled, multiple dose, dose escalation study in subjects with OA knee pain (n=32; 8/cohort). In each cohort, subjects will be randomized 3:1 to receive SC AMG 403 or placebo once every 4 weeks for a total of 4 doses (Q28D x 4).

NCT02318407 Osteoarthritis Drug: AMG 403 Drug: Placebo
MeSH: Osteoarthritis Osteoarthritis, Knee
HPO: Knee osteoarthritis Osteoarthritis

In each cohort, subjects will be randomized 3:1 to receive SC AMG 403 or placebo once every 4 weeks for a total of 4 doses (Q28D x 4). --- Q28D ---

Primary Outcomes

Description: Subject incident of treatment-emergent adverse events, clinically significant changes in vital signs, physical examinations endpoints, clinical laboratory safety tests, and ECGs

Measure: Safety and tolerability as measured by subject incident of treatment-emergent adverse events, clinically significant changes in vital signs, physical examinations endpoints, clinical laboratory safety tests, and ECGs

Time: from 197 days to 211 days

Secondary Outcomes

Description: serum concentrations and derived PK parameters of AMG 403

Measure: Pharmacokinetics profile of AMG 403 including Tmax, AUClast and Cmax

Time: from 197 days to 211 days

2 Randomized Study of Romidepsin Versus the Combination of Romidepsin Plus Pralatrexate in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

This study employs a 1:1 randomization of patients to receive romidepsin alone verses romidepsin plus pralatrexate for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The primary objectives will be to identify a 75% improvement in progression free survival (PFS) among patients receiving the combination compared to single agent romidepsin.

NCT03355768 Lymphoma, T-Cell, Peripheral Drug: Romidepsin Drug: Pralatrexate
MeSH: Lymphoma Lymphoma, T-Cell, Peripheral Lymphoma, T-Cell
HPO: Lymphoma T-cell lymphoma

The every other week (QOW Q28D) schedule had no DLTs at equivalent and higher doses. --- Q28D ---

Primary Outcomes

Description: Compare the progression free survival (PFS) in patients with R/R PTCL treated with romidepsin versus the combination of romidepsin plus pralatrexate.

Measure: Progression Free Survival

Time: up to 3 years

Secondary Outcomes

Description: Contrast the complete response rate (CR) for patients treated with romidepsin or romidepsin plus pralatrexate.

Measure: Complete Response (CR)

Time: up to 3 years

Description: Contrast the duration of response (DOR) for patients treated with romidepsin or romidepsin plus pralatrexate.

Measure: Duration of response (DOR)

Time: up to 3 years

Description: Contrast the overall survival (OS)for patients treated with romidepsin or romidepsin plus pralatrexate.

Measure: Overall survival (OS)

Time: up to 3 years

Description: Contrast the overall response rate (ORR) for patients treated with romidepsin or romidepsin plus pralatrexate.

Measure: Overall response rate (ORR)

Time: up to 3 years

Description: TTP measured for patients with relapsed or refractory PTCL treated with romidepsin or romidepsin plus pralatrexate.

Measure: Time to Treatment Progression (TTP)

Time: up to 3 years

Description: TTR measured for patients with relapsed or refractory PTCL treated with romidepsin or romidepsin plus pralatrexate.

Measure: Time to Relapse (TTR)

Time: up to 3 years

Description: Describe the maximum number of cycles and planned dose intensity of all drugs in both arms in patients with R/R PTCL treated with romidepsin or romidepsin plus pralatrexate.

Measure: Maximum Number of Treatment Cycles

Time: Up to 6 months


HPO Nodes


Osteoarthritis
Genes 85
COL5A2 UFSP2 GNAS COL9A1 MATN3 F8 COMP COL1A1 CANT1 TRPV4 MATN3 MMP13 ZNF687 FRZB CLCN7 COL2A1 COL9A2 SCARB2 MMP13 GHR LMNA COL11A2 LMX1B UFSP2 COL9A3 COL11A2 SLC40A1 GPR101 COL2A1 ACAN TGFB3 SLC26A2 COL11A1 MEFV PHEX COL9A2 TRAPPC2 COL2A1 ZMPSTE24 TRPS1 COL2A1 COL5A1 COMP COL11A2 PHEX AEBP1 COL2A1 CLCN7 COL2A1 ANKH KIF7 EXT2 COL9A3 COL2A1 HGD CCN6 AIP KIF22 ANKH ACAN FBN1 GBA HPGD CCN6 GDF5 ATP7B COL2A1 FGFR3 COMP HLA-B MATN3 TRAPPC2 COL5A1 EXT1 ACAN F9 ASPN COL3A1 COMP COL9A1 SMAD3 COL2A1 TRPV4 COL1A1 SMAD3
Knee osteoarthritis
Genes 4
COL2A1 SMAD3 COL9A2 SMAD3
T-cell lymphoma
Genes 14
POLE FAS CASP10 CTLA4 FAS FASLG CD28 TNFRSF1B RASGRP1 TNFRSF1B PRKCD CTLA4 CD28 NBN
Lymphoma
Genes 133
ATM KRAS CD19 IGH DDX41 BCL10 BIRC3 FOXP1 MS4A1 TP63 RAG1 LIG4 NFKB2 MSH6 TERC RECQL4 NTHL1 WIPF1 CTC1 LYST NOP10 RASGRP1 TNFRSF1B XRCC4 PRKCD NHP2 MAGT1 TNFRSF13B IGH RMRP RUNX1 CTLA4 DCLRE1C FAS ICOS RNF43 NSUN2 XIAP IL7R CASP10 BCL6 CDKN2A ATM IL2RG RTEL1 PARN NBN KIT TNFRSF13C TCF4 ICOS TNFSF12 CHEK2 USB1 CD19 CR2 NRAS MSH2 WAS BCL10 CASP10 MYD88 COL14A1 PRKCD TNFRSF13B MYC MDM2 SH2D1A CCND1 BCL10 CFTR CD27 PGM3 TCF4 CHD7 IGH LIG4 BLM BCL2 TET2 HLA-DRB1 PRSS1 NPM1 KIF11 ITK WRAP53 RAD54B TINF2 FAS DKC1 APC CD81 LIG4 BLM CD28 DKC1 AAGAB RAG2 TNFRSF1B MLH1 TNFRSF13C DNASE1L3 NFKB1 PMS2 ASXL1 IL2RG PRF1 PTEN MALT1 RAD54L CTLA4 CD28 PNP SRSF2 TNFSF12 STAT3 POLE ADA CR2 ADA FASLG PIK3R1 TP53 CTRC ZAP70 MYD88 RB1 RMRP SPINK1 TERT KLHDC8B NBN RHOH